Article
Development of novel high-affinity nanobodies against EGFR for cancer therapy
medRxiv · 2025 · Heitrich, M.; Fernandez, M.; Aguilar-Cortes, D. C.; Werbajh, S.; Canziani, G.; Zylberman, V.; Ripari, L. B.; Videla-Richardson, G. A.; Malchiodi, E. L.; Podhajcer, O. L.; Vinzon, S. E.
Key facts
| Title | Development of novel high-affinity nanobodies against EGFR for cancer therapy |
|---|---|
| First author | Heitrich, M.; Fernandez, M.; Aguilar-Cortes, D. C.; Werbajh, S.; Canziani, G.; Zylberman, V.; Ripari, L. B.; Videla-Richardson, G. A.; Malchiodi, E. L.; Podhajcer, O. L.; Vinzon, S. E. |
| Journal | medRxiv |
| Published | Jan 1, 2025 |
| DOI | 10.1101/2025.03.16.643542 |
| Devices mentioned | BK110039, K042152, K073490, K103302, K800781, K810863, K822496, K940422, K954191, K973350, K982100, K982485 and 1 more |
| Product codes mentioned | CFN, DBM, DFZ, JIT, JLX, KIS, KQP, LFZ, NDS, PCA, KIT, MVU and 2 more |
At a glance
- 10–99 FDA submissions mentioned
- 10–99 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1